IL83220A - Stable pharmaceutical preparation containing granulocyte colony stimulating factor and process for producing the same - Google Patents

Stable pharmaceutical preparation containing granulocyte colony stimulating factor and process for producing the same

Info

Publication number
IL83220A
IL83220A IL83220A IL8322087A IL83220A IL 83220 A IL83220 A IL 83220A IL 83220 A IL83220 A IL 83220A IL 8322087 A IL8322087 A IL 8322087A IL 83220 A IL83220 A IL 83220A
Authority
IL
Israel
Prior art keywords
producing
same
pharmaceutical preparation
stimulating factor
colony stimulating
Prior art date
Application number
IL83220A
Other versions
IL83220A0 (en
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of IL83220A0 publication Critical patent/IL83220A0/en
Publication of IL83220A publication Critical patent/IL83220A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
IL83220A 1986-07-18 1987-07-17 Stable pharmaceutical preparation containing granulocyte colony stimulating factor and process for producing the same IL83220A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP16948686 1986-07-18
JP16948986 1986-07-18
JP16948886 1986-07-18
JP16948786 1986-07-18

Publications (2)

Publication Number Publication Date
IL83220A0 IL83220A0 (en) 1987-12-31
IL83220A true IL83220A (en) 1993-01-31

Family

ID=27474266

Family Applications (1)

Application Number Title Priority Date Filing Date
IL83220A IL83220A (en) 1986-07-18 1987-07-17 Stable pharmaceutical preparation containing granulocyte colony stimulating factor and process for producing the same

Country Status (24)

Country Link
KR (1) KR930004597B1 (en)
CN (1) CN1033738C (en)
AT (1) AT402259B (en)
AU (1) AU611856B2 (en)
BE (1) BE1000253A3 (en)
CA (1) CA1297007C (en)
CH (1) CH671157A5 (en)
DE (1) DE3723781C2 (en)
DK (1) DK171308B1 (en)
ES (1) ES2010226A6 (en)
FR (1) FR2601591B1 (en)
GB (1) GB2193631B (en)
GR (1) GR871067B (en)
HK (1) HK64893A (en)
HU (1) HU198627B (en)
IE (1) IE60290B1 (en)
IL (1) IL83220A (en)
IT (1) IT1218927B (en)
NL (1) NL192917C (en)
NO (1) NO171828C (en)
PT (1) PT85343B (en)
SE (1) SE503312C2 (en)
SG (1) SG64393G (en)
YU (1) YU47543B (en)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4929442A (en) * 1986-09-26 1990-05-29 Exovir, Inc. Compositions suitable for human topical application including a growth factor and/or related materials
US4847325A (en) * 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
NZ228285A (en) * 1988-03-11 1991-08-27 Teikoku Seiyaku Kk Pharmaceutical composition comprising a polypeptide and adapted for intravaginal administration
US5981485A (en) 1997-07-14 1999-11-09 Genentech, Inc. Human growth hormone aqueous formulation
US6132763A (en) * 1988-10-20 2000-10-17 Polymasc Pharmaceuticals Plc Liposomes
US5349052A (en) * 1988-10-20 1994-09-20 Royal Free Hospital School Of Medicine Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor
GB8824591D0 (en) * 1988-10-20 1988-11-23 Royal Free Hosp School Med Fractionation process
US5104651A (en) * 1988-12-16 1992-04-14 Amgen Inc. Stabilized hydrophobic protein formulations of g-csf
JP3249147B2 (en) * 1990-06-01 2002-01-21 キリン−アムジエン・インコーポレーテツド Oral preparation containing bioactive protein
EP0459516A1 (en) * 1990-06-01 1991-12-04 Kirin-Amgen, Inc. Oral dosage form of biologically active proteins
FR2686899B1 (en) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa NOVEL BIOLOGICALLY ACTIVE POLYPEPTIDES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
FR2686900B1 (en) * 1992-01-31 1995-07-21 Rhone Poulenc Rorer Sa NOVEL POLYPEPTIDES HAVING GRANULOCYTE COLONY STIMULATION ACTIVITY, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
FR2693907B1 (en) * 1992-07-23 1994-09-02 Rhone Poulenc Rorer Sa A method of administering granulocyte colony stimulating factor solutions.
EP0582932A1 (en) * 1992-08-11 1994-02-16 F. Hoffmann-La Roche Ag Therapeutic system for the parenteral administration of hematopoietic growth factors
DE4242919A1 (en) * 1992-12-18 1994-06-23 Boehringer Mannheim Gmbh Process for the preparation of storage-stable aqueous pharmaceutical preparations of G-CSF
DE4242863A1 (en) * 1992-12-18 1994-06-23 Boehringer Mannheim Gmbh Stable lyophilized pharmaceutical preparations of G-CSF
US20030053982A1 (en) 1994-09-26 2003-03-20 Kinstler Olaf B. N-terminally chemically modified protein compositions and methods
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
AU695129B2 (en) * 1995-02-06 1998-08-06 Genetics Institute, Llc Formulations for IL-12
TW434021B (en) * 1995-03-15 2001-05-16 Kirin Brewery Methods for preventing adsorption of thrombopoietin (TPO), and stable TPO-containing compositions
TW434020B (en) * 1995-03-15 2001-05-16 Kirin Brewery Methods for preventing adsorption of thrombopoietin (TPO), and stable top-containing compositions
GB9526733D0 (en) 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
US20030190307A1 (en) 1996-12-24 2003-10-09 Biogen, Inc. Stable liquid interferon formulations
JP3895109B2 (en) * 1998-03-06 2007-03-22 中外製薬株式会社 Protein-free formulation
US6979442B1 (en) * 1998-08-17 2005-12-27 Pfizer Inc. Stabilized protein compositions
TWI245645B (en) * 1999-09-08 2005-12-21 Chugai Pharmaceutical Co Ltd Protein solution formulations and stabilization methods thereof
TR200401573T4 (en) 2000-02-29 2004-08-23 Pfizer Products Inc. Stabilized granulocyte colony stimulating factor
WO2001064241A1 (en) * 2000-02-29 2001-09-07 Chugai Seiyaku Kabushiki Kaisha Preparations stabilized over long time
US6946134B1 (en) 2000-04-12 2005-09-20 Human Genome Sciences, Inc. Albumin fusion proteins
JP2003530839A (en) 2000-04-12 2003-10-21 プリンシピア ファーマスーティカル コーポレイション Albumin fusion protein
AU2001282607B2 (en) * 2000-09-01 2006-08-17 Chugai Seiyaku Kabushiki Kaisha Solution preparations stabilized over long time
US8435939B2 (en) 2000-09-05 2013-05-07 Biokine Therapeutics Ltd. Polypeptide anti-HIV agent containing the same
US7507413B2 (en) 2001-04-12 2009-03-24 Human Genome Sciences, Inc. Albumin fusion proteins
EP2261250B1 (en) 2001-12-21 2015-07-01 Human Genome Sciences, Inc. GCSF-Albumin fusion proteins
EP1541585B1 (en) 2002-08-27 2013-01-30 Biokine Therapeutics Ltd. Cxcr4 antagonist and use thereof
AU2004216298B2 (en) 2003-02-28 2009-04-23 Chugai Seiyaku Kabushiki Kaisha Stabilized protein-containing formulations
DE202006020194U1 (en) 2006-03-01 2007-12-06 Bioceuticals Arzneimittel Ag G-CSF liquid formulation
EP3011961B1 (en) 2006-12-21 2020-11-11 Biokine Therapeutics LTD. 4f-benzoyl-tn14003 for the mobilisation of hematopoietic progenitor cells in view of transplantation
EP2396023A2 (en) 2009-02-11 2011-12-21 Yeda Research and Development Co. Ltd. Short beta-defensin-derived peptides
RU2519031C1 (en) 2010-01-19 2014-06-10 Ханми Сайенс Ко., Лтд. Liquid formulations for long-acting conjugate of g-csf
EP2399572A1 (en) 2010-06-22 2011-12-28 Sandoz AG Long-term storage of non-glycosylated recombinant human G-CSF
KR20210089270A (en) 2015-07-16 2021-07-15 바이오카인 테라퓨틱스 리미티드 Compositions and methods for treating cancer
BR112018016924A2 (en) 2016-02-23 2019-01-02 Biokine Therapeutics Ltd treatment regimen selection method for individual who has acute myeloid leukemia (LMA), acute response myeloid leukemia (LMA) treatment maximization method, lma treatment method, cxcr4 antagonist, and chemotherapeutic agent in the treatment of lma
WO2018138267A1 (en) 2017-01-27 2018-08-02 Cinfa Biotech S.L. Method for determining the efficacy of a g-csf containing composition
EP3797752A4 (en) * 2018-05-21 2022-03-02 Chugai Seiyaku Kabushiki Kaisha Lyophilized formulation sealed in glass vial

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2652636A1 (en) * 1976-11-19 1978-05-24 Hans Uwe Dr Rer Nat Wolf Stabilising protein during separation, purification and storage - by adding amphiphilic cpds., esp. lipid(s), ionic and or nonionic detergents
SE451844B (en) * 1978-03-20 1987-11-02 Morinaga Milk Industry Co Ltd GLYCOPROTEIN, PROCEDURE FOR PREPARING THEREOF AND THERAPEUTIC AGENTS INCLUDING THE GLYCOPROTEIN
US4609546A (en) * 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
JPS60228422A (en) * 1984-04-26 1985-11-13 Suntory Ltd Stabilized preparation of physiologically active substance
JPS61227526A (en) * 1984-07-25 1986-10-09 Chugai Pharmaceut Co Ltd Novel csf and method of collecting same
JPS6191131A (en) * 1984-10-09 1986-05-09 Chugai Pharmaceut Co Ltd Method and composition for preventing adsorption of pharmaceutical
DE3686794T2 (en) * 1985-02-05 1993-03-04 Cetus Oncology Corp CLEANING THE NATURAL COLONY-STIMULATING FACTOR-1.
US4810643A (en) * 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
JPH0618778B2 (en) * 1985-10-04 1994-03-16 中外製薬株式会社 Leukopenia treatment

Also Published As

Publication number Publication date
BE1000253A3 (en) 1988-09-27
SE8702907L (en) 1988-01-19
IE60290B1 (en) 1994-06-29
DK171308B1 (en) 1996-09-02
DK368387D0 (en) 1987-07-15
ATA177587A (en) 1996-08-15
PT85343A (en) 1987-08-01
FR2601591B1 (en) 1991-04-26
SG64393G (en) 1993-08-06
AU7566587A (en) 1988-01-21
GB2193631B (en) 1990-11-21
NL192917C (en) 1998-05-07
ES2010226A6 (en) 1989-11-01
HK64893A (en) 1993-07-16
NO171828B (en) 1993-02-01
AT402259B (en) 1997-03-25
SE8702907D0 (en) 1987-07-17
DE3723781A1 (en) 1988-01-21
IE871933L (en) 1988-01-18
YU47543B (en) 1995-10-03
DE3723781C2 (en) 1999-09-02
PT85343B (en) 1990-04-30
IL83220A0 (en) 1987-12-31
GB2193631A (en) 1988-02-17
CN1033738C (en) 1997-01-08
DK368387A (en) 1988-01-19
FR2601591A1 (en) 1988-01-22
AU611856B2 (en) 1991-06-27
NO872966D0 (en) 1987-07-16
CN87104963A (en) 1988-02-24
IT8767594A0 (en) 1987-07-10
HUT44941A (en) 1988-05-30
NL192917B (en) 1998-01-05
IT1218927B (en) 1990-04-24
YU134287A (en) 1989-06-30
NO872966L (en) 1988-01-19
KR880001297A (en) 1988-04-22
CA1297007C (en) 1992-03-10
KR930004597B1 (en) 1993-06-01
NL8701640A (en) 1988-02-16
GB8716904D0 (en) 1987-08-26
SE503312C2 (en) 1996-05-13
NO171828C (en) 1993-05-12
GR871067B (en) 1987-11-19
CH671157A5 (en) 1989-08-15
HU198627B (en) 1989-11-28

Similar Documents

Publication Publication Date Title
GB2193631B (en) Stable pharmaceutical preparation containing granulocyte colony stimulating factor and process for producing the same
HUT40453A (en) Process for producing 11-beta-phenyl-gonanes and pharmaceutical compositions containing them
HUT45954A (en) Process for producing tetrahydronaphtalene- and indanederivatives and pharmaceutical compositions containing them
HUT41772A (en) Process for producing /4-substituted-piperazinyl- and -homopiperazinyl/-pyridazines and pharmaceutical compositions containing them
HUT48611A (en) Process for producing isoflavans and pharmaceutical compositions comprising same
HUT41418A (en) Process for producing pharmaceutical compositions containing anticoagulator polipeptides and process for producing the active agents
HUT47274A (en) Process for producing terciary hydroxy-alkyl-xantines and pharmaceutical compositions containing them as active components
EP0187620A3 (en) Pyrrolo-pyrroles, process for their preparation and use
HUT47278A (en) Process for producing pyrrolo-benzimidazols and pharmaceutical compositions containing them
GR860849B (en) 4-demethyl -4- epipodophyllotoxin derivatives process for their preparation and their use as medicaments
PT81835B (en) Process for the preparation of spirodioxolanes spirodithiolanes and spirooxothiolanes
HU886790D0 (en) Neutrophilous activating factor and process for its preparation
HUT46303A (en) Process for producing 3-/omega-/3,5-di-/tetrabutil/-4-hydroxy-phenyl/-alkanoyl/-pyrroles andtheyr deoxy-analogues and pharmaceutical compositions containing them
ZA875268B (en) Stable pharmaceutical preparation containing granulocyte colony stimulating factor and process for producing the same
GR861024B (en) Process for the preparation of 5-pyrimidinecarboxamides and treatment of leukemia and tummors therewith
IL79163A0 (en) 1,8-bridged 4-quinolone-3-carboxylic acids,their preparation,medicaments containing them and their use for the preparation of medicaments
HUT41762A (en) Process for producing thieno-benzo-pyranes, -thiopyranes and naphtothiophenes and pharmaceutical compositions containing them
HUT44524A (en) Process for producing 1,3-thiazolyl- or 1,3,4-thiadiazolyl- derivatives and pharmaceutical compositions containing them
GR862249B (en) Dihydropyridin-2-hydroxyamine process for their preparation and their use as medicaments
GR870093B (en) 8a- acylaminoergolines their production and pharmaceutical compositions containing them
PT82019A (en) Process for the preparation of arylglycidyl ethers and 3-substituted 1-alkylamino-2-propanols
HUT47849A (en) Process for producing new pharmaceutical with analgetic and hypertonicity-relaxing effect
ZA869560B (en) New ortho-anisamides,process for their preparation and their therapeutic applications
ZA859745B (en) Mixture of different dihydropyridines,process for the preparation thereof and the use thereof in medicaments
DE3660220D1 (en) Process for the preparation of chloronitroanilines and chloronitrophenols

Legal Events

Date Code Title Description
KB Patent renewed
KB Patent renewed
KB Patent renewed
EXP Patent expired